Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Advanced Fallopian Tube Carcinoma 1

Interventions

pembrolizumab 550Specimen Handling 462Carboplatin 441Magnetic Resonance Spectroscopy 429Cyclophosphamide 412Cisplatin 398Radiotherapy 313Gemcitabine 310Bevacizumab 306Paclitaxel 294Biopsy 259Drug Therapy 248Capecitabine 241Oxaliplatin 239fludarabine 238Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 202Dexamethasone 186Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 145durvalumab 143Leucovorin 138atezolizumab 137toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Diphtheria Toxoid × Clear all
NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡